XTalPi and Visen Pharmaceuticals have announced a project agreement and a long-term strategic partnership, with a collaboration scale reaching tens of millions of yuan. The two parties will combine XTalPi's AI+robotics drug development platform with Visen Pharmaceuticals' expertise in the endocrine field to jointly advance the early discovery and clinical translation of innovative therapies for high clinical value indications and innovative targets in the endocrine and metabolic fields. The endocrine and metabolic market is expected to grow from $95.9 billion in 2024 to nearly $200 billion by 2031. In this collaboration, XTalPi will utilize its AI drug development platform to accelerate the discovery of preclinical candidate compounds, while Visen Pharmaceuticals will provide biological expertise and full-chain commercialization capabilities to ensure that the molecules meet clinical needs and achieve commercial value. In the future, the two parties will explore more challenging drug targets and jointly create an innovative collaboration ecosystem. Ma Jian, CEO of XTalPi, and Lu Anbang, CEO of Visen Pharmaceuticals, both expressed anticipation for this collaboration.